cd4+t cell

ML604440 is a cell permeable proteasome β1i (LMP2) subunit inhibitor.

Anisperimus (LF 15-0195) is an immunosuppressant that enhances activation-induced T-cell death by promoting caspase-8 and caspase-10 activation at the DISC level, and prevents CNS autoimmunity by promoting the development of Foxp3-expressing regulatory CD4 T cells.

SMU-L11 is a specific TLR7 agonist (EC50=0.024 μM) that recruits the MyD88 adaptor protein, activating downstream NF-κB and MAPK signaling pathways. In mouse models, SMU-L11 significantly enhances immune cell activation and boosts CD4+ T and CD8+ T cell proliferation, leading to direct tumor cell destruction and inhibition of tumor growth. This compound has applications in cancer research and potential in studying immune system disorders.

ARN-6039, an orally available inverse agonist of RORγ, targets Autoimmune Neuroinflammatory Demyelinating Disease. Its efficacy was demonstrated in a RORγ-activated IL-17A Prom/LUCPorter assay in HEK 293 cells (360 nM) and in IL-17 release from CD4+T cell assays (220 nM).

CAY10774 is an inhibitor of the protein-protein interaction between programmed cell death 1 (PD-1) and its ligand PD-L1 (IC50= 15 nM in a homologous time-resolved fret (HTRF) assay).1It increases the activation of Jurkat cells expressing PD-1 in co-culture with artificial antigen-presenting cells (aAPCs) expressing PD-L1 (EC50= 6.6 μM in a reporter assay). CAY10774 increases surface expression of PD-1 on primary human CD4+and CD8+T cells co-cultured with aAPCs. 1.Konieczny, M., Musielak, B., Kocik, J., et al.Di-bromo-based small-molecule inhibitors of the PD-1/PD-L1 immune checkpointJ. Med. Chem.63(19)11271-11285(2020)

Glucosamine 6-sulfate (GlcN6S) is a glucosamine derivative exhibiting anti-inflammatory effects in experimental autoimmune encephalomyelitis (EAE). It inhibits gene expression of IL-12, T-bet, and IFN-γ, suppresses Th1 CD4 T cell differentiation, and may be utilised in multiple sclerosis (MS) research.

Influenza Matrix Protein (61-72) is a peptide derived from the matrix protein of influenza viruses, encompassing amino acids 61-72, and has the ability to elicit a CD4+ T-cell response.

Cyclotriazadisulfonamide (CADA) is a selective, CD4-targeted HIV inhibitor and Sec61 inhibitor that downregulates CD4 T-cell receptors and restricts CD4 translocation, thereby limiting HIV binding and entry. It exhibits activity against multiple HIV strains.

LCMV GP (61-80) is a 61-80 amino acid sequence peptide fragment derived from the lymphocytic choroid plexus meningitis virus (LCMV) glycoprotein (GP), which is a specific antigenic determinant that induces CD4+ T cell responses.

Carbomethoxycarbonyl-D-Pro-D-Phe-OBzl is an HIV-1 inhibitor that interacts with gp120, preventing its binding to CD4 and thereby maintaining CD4-dependent T cell function.

PD-1/PD-L1-IN-26 (Compound II-14) is a potent PD-1/PD-L1 inhibitor with an IC50 of 0.0380 μM. It enhances the immune microenvironment by promoting CD4+ T cell infiltration into tumor tissues, suggesting its potential application in cancer research [1].

Forigerimod (IPP-201101), a potent CD4 T-cell modulator, is a 21-amino-acid fragment of the U1 small nuclear ribonucleoprotein 70 kDa, phosphorylated at Ser140, known for its ability to inhibit autophagy effectively. It has applications in researching autoimmune disorders, including systemic lupus erythematosus (SLE) [1] [2] [3] [4].

Forigerimod TFA (IPP-201101 TFA), a CD4 T-cell modulator, is a phosphorylated 21-amino-acid fragment derived from U1 small nuclear ribonucleoprotein 70 kDa, specifically at Ser140. It notably inhibits autophagy and is utilized in researching autoimmune disorders, including systemic lupus erythematosus (SLE) [1] [2] [3] [4].

MOG peptide (35-55), mouse, rat acetate, is a minor component of central nervous system myelin with encephalitogenic activity. It can induce CD4⁺ T cell proliferation and Th1-type immune responses, leading to relapsing-remitting demyelinating disease. It is commonly used to establish experimental autoimmune encephalomyelitis (EAE) models.

Keliximab (SB-210396), a chimeric human/macaque IgG1 anti-CD4 monoclonal antibody, demonstrates a binding affinity for soluble CD4 with a K i value of 1.0 nM. It inhibits T cell proliferation and IL-2 production, making it a valuable agent for cancer research [1] [2].

MOG peptide (35-55) amide, a myelin oligodendrocyte glycoprotein (MOG) fragment spanning amino acids 35 to 55, selectively stimulates CD4+ T cell expansion and induces experimental autoimmune encephalomyelitis (EAE) in animal models [1] [2] [3].

Ivuxolimab is a fully human immunoglobulin G2 (IgG2) monoclonal antibody functioning as an agonist that targets the OX40 receptor (CD134), which selectively binds to the OX40 receptor expressed on the surface of activated CD4+ and CD8+ T cells without inducing antibody-dependent cellular cytotoxicity. Ivuxolimab can promote T cell proliferation, enhance cell survival, stimulate cytokine secretion (such as IFN-γ and IL-2), inhibit the suppressive function of regulatory T cells (Tregs), and potentiate anti-tumor immune responses, enabling its use in the study of cancers including melanoma, hepatocellular carcinoma, and head and neck squamous cell carcinoma.

Tregalizumab (BT-061) is a humanised monoclonal antibody targeting CD4, capable of binding unique epitopes on CD4 and selectively inducing regulatory T cell (Treg) activation. It holds potential applications in immunology and inflammation.

Rosnilimab (ANB030) is a programmed cell death protein 1 (PD-1) agonist that can inhibit antigen-driven T cell proliferation, reduce the secretion of pro-inflammatory cytokines, and deplete CD4 and CD8 T cell populations characterized by high PD-1 expression, thereby enabling its use in the research of various inflammatory diseases such as colitis and rheumatoid arthritis.

Semzuvolimab, a murine IgG1κ antibody, targets the p55 T-cell surface antigen T4/Leu-3 (CD4). It has demonstrated capabilities to neutralize HIV infection and may inhibit HIV in patients on stable highly active antiretroviral therapy (HAART) [1] [2].

Zanolimumab is a humanised monoclonal antibody targeting CD4, exhibiting cytotoxic and antiproliferative properties. By binding to the CD4 molecule and blocking T cell receptor (TCR) signalling, it is used in the treatment of autoimmune diseases such as rheumatoid arthritis, psoriasis, and T-cell lymphoma.

Tetanus Toxin (830–844), a biologically active peptide and a tetanus toxin-derived peptide TT830–844 CD4+ T-cell epitope, exhibits promiscuity by binding to a wide spectrum of HLA–DRB molecules. Consequently, it is anticipated to elicit CD4+ T-cell responses across a broad segment of the human population.

HOXB7 8–25 (MDM2 32-46) is a peptide epitope derived from MDM2 that can induce antigen-specific and tumor-reactive CD4+ T cell responses [1].

TPP-1, a peptide inhibitor, targets the interaction between programmed cell death protein 1 (PD-1) and its ligand (PD-L1), binding specifically to PD-L1 with a dissociation constant (Kd) of 94.67 nM. At a concentration of 20 µM, TPP-1 effectively counteracts the PD-L1-induced suppression of IFN-γ production in anti-CD3-stimulated isolated human CD4+ T cells. Furthermore, TPP-1 demonstrates significant efficacy in reducing tumor volume in a mouse xenograft model of HL-60 leukemia. This model involved HL-60 cells co-cultured with anti-CD3-activated isolated human CD4+ T cells, with TPP-1 administration at a dosage of 4 mg/kg showing notable antitumor activity.